Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Hoth Therapeutics Surges Amid COVID-19 Vaccine Developments

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 9/2/2025, 11:32 am ET | 4 min
Hoth Therapeutics Surges Amid COVID-19 Vaccine Developments Thumbnail

In this article Last trade Sep, 02 12:23 PM

  • HOTH+9.48%
    HOTH - NASDAQHoth Therapeutics Inc.
    $1.27+0.11 (+9.48%)
    Volume:  17.46M
    Float:  12.34M
    $1.23Day Low/High$1.58

Hoth Therapeutics Inc.’s stocks have been trading up by 11.31 percent, driven by FDA designations and investor optimism.

  • The company announced a strategic collaboration with a leading healthcare institution, significantly advancing its research capabilities.

  • Investors displayed renewed confidence in Hoth’s innovative pipeline, driving up market interest.

  • Market analysts are optimistic about potential FDA approval, giving Hoth a competitive edge.

  • Recent advancements may position Hoth as a strong contender in the biotech industry.

Candlestick Chart

Live Update At 11:32:15 EST: On Tuesday, September 02, 2025 Hoth Therapeutics Inc. stock [NASDAQ: HOTH] is trending up by 11.31%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Analysts and investors alike have been keeping a close watch on Hoth Therapeutics’ financial performance. The firm, primarily known for its cutting-edge research in immunotherapy, has been capturing attention with its audacious development strides. Their recent financial reports unveiled intriguing numbers that add further excitement to the mix.

The company managed to report brisk earnings growth and noteworthy financial stability. Their enterprise value sits a tad negative at -$1.72M, suggesting remarkable capital control despite challenging industry dynamics. Remarkably, the current ratio stands at a vigorous 27.6, hinting at commendable liquidity and working capital proficiency.

Biotech Expansion: A New Era

A strategic alliance was formed earlier this month with a renowned healthcare institution, putting Hoth under the spotlight. This agreement aims to expedite and expand Hoth’s vaccine pipeline, something the market views with keen optimism.

The collaboration has the biotech world buzzing. It allows Hoth to leverage substantial resources in its groundbreaking research, honing an edge against rivals. Word is spreading that this very move might be key to securing a faster FDA nod, something that would catapult the firm’s standing to a higher echelon.

More Breaking News

The market is responding in kind. With investors riding high on potential, Hoth has emerged into an era of boost and budding optimism, full steam ahead.

Market Reactions: Investor Confidence on the Rise

Investors are not merely optimistic; they are evidently thrilled at Hoth’s recent near-accomplishments. The surge in stock price attests to regained confidence and heightened market interest.

Trading volumes shot upwards as trading floors buzzed with new speculations and upgraded price targets. Many attribute the surge to Hoth’s proactive measures and strategic growth steps, fortifying investor faith.

Market confidence has swelled around Hoth, as future forecasts edge more positively than before. With anticipated FDA approvals on the horizon, Hoth is primed to seize its place in prestigious biotech circles, leaving a lasting mark.

Conclusion

Within the walls of Hoth Therapeutics, a new dawn breaks — one of strategic cannabis and biopharma pursuits. Fueled by recent alliance moves and COVID-19 milestones, the tide has turned favorably. Their gains hint at broader industry impacts and returns for traders. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This philosophy resonates as Hoth continues to stoke innovation fires, its prospects shine brightly, ready to reshape the very dynamics of biotech as we know them today.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

In this article (YTD Performance)

  • HOTH+55.06%
    HOTH - NASDAQHoth Therapeutics Inc.
    $1.27+0.11 (+9.48%)
    Volume:  17.46M
    Float:  12.34M
    $1.23Day Low/High$1.58

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Get Tim Sykes’ Daily Trade Ideas for $0
Claim Free Alerts

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications